| Field | Specification |
|---|---|
| Target | |
| Alternative names | High mobility group protein B1;High mobility group protein 1;HMG-1;HMGB1;HMG1; |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthesized peptide derived from human HMGB1 |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Liquid |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone AAC-8 is a rabbit monoclonal antibody that recognizes high mobility group protein B1 (gene HMGB1) in human, mouse and rat samples and is validated for Western blot, IHC, ICC/IF and flow cytometry. The predicted molecular weight is 24.9 kDa, and the supplier reports an observed band at about 25 kDa.
HMGB1 is an abundant non-histone chromatin protein that bends DNA and assists transcription, DNA repair and V(D)J recombination. When released from dying or activated cells it acts as a danger signal (DAMP) that engages receptors such as RAGE and TLR4, and it is widely measured in studies of inflammation, sepsis, tissue injury and cell death.
| Target | High mobility group protein B1 (gene HMGB1; UniProt P09429, human) |
|---|---|
| Clone | AAC-8 |
| Host / Clonality / Isotype | Rabbit / Monoclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Liquid |
| Formulation | PBS (pH 7.4); 150 mM NaCl; 0.02% sodium azide; 50% glycerol; plus stabilizers |
| Calculated MW | 24.9 kDa |
| Observed MW | 25 kDa |
| Storage | Long term: −20 °C for up to 12 months. Frequent use: 4 °C for up to 1 month. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 1:500–1:2000 |
|---|---|
| Immunohistochemistry | 1:50–1:200 |
| Immunocytochemistry / Immunofluorescence | 1:50–1:200 |
| Flow cytometry | 1:30 |
Samples with a confirmed band (WB): human HeLa cells, human 293T cells, human K562 cells, human Jurkat cells, human HeLa- WT cells, human HeLa-HMGB1 KO cells, rat brain tissue, rat liver tissue, mouse brain tissue, mouse liver tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 1:1000 overnight at 4 °C, HRP-conjugated secondary antibody at 1:1000, ECL detection.
Samples with confirmed staining (IHC): human colorectal adenocarcinoma tissue, human lung adenocarcinoma tissue, human spleen tissue, human prostatic acinar adenocarcinoma tissue, human cervical squamous carcinoma tissue, rat liver tissue, rat kidney tissue, mouse skeletal muscle - gastrocnemius tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): HeLa cells.
Immunogen
Synthetic peptide based on the sequence of human HMGB1.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt describes high mobility group protein B1 as secreted and also located in the nucleus, chromosome and cytoplasm. Tissue expression noted by UniProt (human): Ubiquitous. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Yanlu Yu et al. (2025) Biomimetic-Nanoparticle-Enhanced Photothermal Immunotherapy: Targeted Delivery of Near-Infrared Region II Agents and Immunoadjuvants for Tumor Immunogenicity. Biomaterials Research. 10.34133/bmr.0151
Haoran Liu et al. (2019) H19 promote calcium oxalate nephrocalcinosis-induced renal tubular epithelial cell injury via a ceRNA pathway. EBioMedicine. 10.1016/j.ebiom.2019.10.059
Shang-Qing Huang et al. (2021) Abdominal paracentesis drainage attenuates intestinal inflammation in rats with severe acute pancreatitis by inhibiting the HMGB1-mediated TLR4 signaling pathway. World Journal of Gastroenterology. 10.3748/wjg.v27.i9.815
Tao Xiong et al. (2024) n-3 polyunsaturated fatty acids alleviate the progression of obesity-related osteoarthritis and protect cartilage through inhibiting the HMGB1-RAGE/TLR4 signaling pathway. International Immunopharmacology. 10.1016/j.intimp.2024.111498
Yi Wen et al. (2020) Abdominal paracentesis drainage ameliorates myocardial injury in severe experimental pancreatitis rats through suppressing oxidative stress. World Journal of Gastroenterology. 10.3748/wjg.v26.i1.35
Wenhai Zhou et al. (2016) MicroRNA-205‑5b inhibits HMGB1 expression in LPS-induced sepsis. International Journal of Molecular Medicine. 10.3892/ijmm.2016.2613
Xiaorong Hu et al. (2017) The HMGB1‑IL‑17A axis contributes to hypoxia/reoxygenation injury via regulation of cardiomyocyte apoptosis and autophagy. Molecular Medicine Reports. 10.3892/mmr.2017.7839
Jia Jie et al. (2017) Propofol inhibits the release of interleukin-6, 8 and tumor necrosis factor-α correlating with high-mobility group box 1 expression in lipopolysaccharides-stimulated RAW 264.7 cells. BMC Anesthesiology. 10.1186/s12871-017-0441-0
M. Li et al. (2018) High-Mobility Group Box 1 Protein Regulates Autophagy in LO2 Cells Following Anoxia-Reoxygenation Injury. Transplantation Proceedings. 10.1016/j.transproceed.2018.03.002
